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21 1. Introduction
22 Genistein-7-glucoside [G7G (Figure 1A)] is a natural conjugated isoflavone — i.e. a 
23 plant derived polyphenolic molecule capable of exerting oestrogenic effects; 
24 otherwise known as a phytoestrogen. G7G is found in a range of foods including 
25 lentils, soybeans, and coffee [1,2]. Following ingestion, G7G is hydrolysed in the 
26 intestine [3] to release the aglycone form, genistein (Figure 1B), which is rapidly 
27 absorbed by the upper intestine [4] and circulates readily in the blood [5,6].
28 Soya derivatives are a major component of several foodstuffs, including human milk-
29 replacers, which are high in genistein-7-glucoside. Furthermore, soy has long been 
30 popular in eastern societies, with intake increasing rapidly in western societies [7]. In 
31 dietary supplements and extracts, the content of isoflavone aglycones as a percentage 
32 of total isoflavones can range from 15% to 85% [8]. Furthermore the rising inclusion 
33 of soy in processed foods represents the new primary source of isoflavones in UK 
34 diets [7,9].
35 Unlike G7G, [10], the unconjugated flavonoid genistein has been observed in the 
36 blood in concentrations of approximately 20 ng.ml-1 [8] which is unsurprising given 
37 the 1998 UK Total Diet Survey estimated that the average adult daily intake of 
38 genistein is 3 mg.day-1.
39 Flavonoids such as genistein reportedly exert numerous beneficial physiological 
40 effects [11-13]. For example, genistein can lower blood pressure by up-regulating 
41 nitric oxide (NO) synthesis in the vascular endothelium [14-16]. Furthermore, 
42 genistein inhibits cell growth and MAP kinase activity in aortic smooth muscle [17], 
43 increases TGF-β secretion [18], and is implicated in antioxidant protection of DNA 
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44 and low-density lipoprotein, and systemic processes such as the modulation of 
45 inflammation, inhibition of platelet aggregation, and modulation of adhesion receptor 
46 expression [19-23].
47 The diverse biological activity of genistein is generally assumed to be a consequence 
48 of its chemical structure (Figure 1B), which resembles 17β-oestradiol (E2) (Figure 
49 1C). Genistein can bind to oestrogen receptors (ERs) in vivo and is able to exert 
50 modest oestrogenic effects [24]. It can promote dimerisation of ERs and subsequent 
51 DNA binding at oestrogen response elements (EREs), similarly to E2, thus 
52 modulating gene expression [25]. The oestrogenic potency of genistein on ERα and 
53 and ERβ is 198% and 182% of that of E2 respectively [26] Genistein has been shown 
54 to be effective at activating oestrogen receptors in vitro at 1 mM [16].
55 Although the reproductive significance of E2 is well established, the effects of 
56 genistein on reproductive physiology are less well understood. Newbold and 
57 coworkers [27] reported that mice treated neonatally (Days 1-5) with genistein in vivo 
58 developed uterine adenocarcinoma at 18 months. Since then the same group has 
59 shown that circulating maternal genistein perturbs the implantation process [28] in 
60 addition to disrupting the ability of the oviduct to support physiological embryo 
61 cleavage [29]. In a similar study Jefferson and coworkers [30] found that feeding mice 
62 with genistein perturbed the expression of several immune response genes in the 
63 oviduct epithelium, a consequence of which was an increased in embryo cleavage and 
64 a decreased ratio of trophectoderm to inner cell mass cells in the developing offspring 
65 in vivo. Although this did not affect full term development after embryo transfer, 
66 these cumulative findings highlight the potential of genistein to compromise offspring 
67 health. In spite of these studies, the presence of genistein in the female reproductive 
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68 tract has never been confirmed.
69 Building on these findings, the in vitro oviduct model recently established by 
70 Simintiras and coworkers [31] has been used to investigate whether effects of dietary 
71 genistein on the developing conceptus may be direct or indirect. The research 
72 questions of this study therefore are: (a) does genistein traverse the oviduct 
73 epithelium, thereby permitting a direct effect on the embryo? (b) Does genistein 
74 supplementation impact the amino acid composition of in vitro derived oviduct fluid 
75 (ivDOF), thus potentially affecting the embryo indirectly? (c) If so, is the amino acid 
76 profile similar to that of E2?
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77 2.  Materials and Methods
78 Unless stated otherwise all reagents were purchased from Sigma Aldrich UK.
79 2.1.  Tissue Harvest
80 Abattoir-derived bovine reproductive tracts were transported to the laboratory at room 
81 temperature in Hank’s Buffered Salt Solution (HBSS) (without CaCl2 and MgCl2) 
82 supplemented with 10 mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid, N-
83 (2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES) and 1 μM 
84 Aprotonin. Primarily stage II [32] reproductive tracts reached the laboratory within 90 
85 minutes of slaughter. Whole oviducts were dissected and cell isolation was performed 
86 manually into petri dishes containing HBSS without CaCl2 and MgCl2. The cell 
87 suspension was centrifuged for 5 mins at 400 x g at room temperature. The 
88 supernatant and upper layer containing erythrocytes was discarded and the pellet 
89 resuspended in 10 ml HBSS and further centrifuged for 5 minutes at 350 x g. Pellets 
90 were resuspended in 1 ml culture medium – consisting of 1:1 Dulbecco’s Modified 
91 Eagle’s Medium DMEM and Nutrient Mixture F12 Ham; supplemented with 265 U/ 
92 ml Penicillin-Streptomycin, 20 μg/ml Amphotericin B, 2 mM L-Glutamine, 2.5% 
93 (v/v) Newborn Calf Serum (NCS), 2.5% (v/v) Foetal Bovine Serum (FBS), and 0.75% 
94 (w/v) Bovine Serum Albumin (BSA). Similarly to Simintiras and coworkers [31] 
95 bovine oviduct epithelial cells (BOECs) were subsequently isolated from fibroblasts 
96 based on their differential adhesion times — cells were initially seeded together in 
97 T75 flasks and following 18 hours of culture, BOECs (un-adhered) were removed 
98 [33].
99 2.2.  BOEC Culture
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100 Isolated BOECs were directly seeded onto the apical fascia of 24 mm Corning 
101 TranswellTM 0.4 μM pore Polyethylene Terephthalate (PET) cell culture inserts coated 
102 with 10 μg/ml laminin at a density of 1 x 106 cells/ml/insert. BOECs were 
103 subsequently maintained between two culture media-filled chambers; apical and 
104 basal, with 2 ml culture medium in each compartment, at 39°C in 5% CO2, 95% air. 
105 Apical and basal media were replaced every 48 hours and a polarised confluent 
106 monolayer was achieved after ~ 7 days as determined by Transepithelial 
107 Electrochemical Resistance.
108 2.3 Transepithelial Electrochemical Resistance 
109 Transepithelial Electrochemical Resistance (TEER) was measured using an Evom 
110 voltmeter fitted with handheld chopstick electrodes (World Precision Instruments). 
111 The TEER of a tight BOEC monolayer was between 700 Ω/cm2 to 1000 Ω/cm2 
112 [31,34,35]. In addition to assessing monolayer confluence prior to experimentation, 
113 TEER was utilised as a measure of post-treatment cellular integrity.
114 2.4. In vitro Derived Oviduct Fluid 
115 Upon reaching confluence BOECs were cultured in an apical-basal air-liquid 
116 interface. The basal medium comprised 2 ml of culture medium while the apical 
117 compartment comprised moist air in 5% CO2. Following 24 hours of post-confluence 
118 air-liquid interface incubation, a thin film of fluid formed in the apical chamber — 
119 termed in vitro derived oviduct fluid (ivDOF). ivDOF was isolated for analysis. The 
120 term ‘native’ is used to describe ivDOF resulting from untreated epithelia [31].
121 2.5. Genistein Transport Studies
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122 BOECs were incubated for 20 minutes at 39°C in 5% CO2 in a liquid-liquid interface 
123 of 4 ml (2 ml apically and basally) normal Krebs Ringer (KR) solution, after which, 
124 genistein transport experiments were conducted by supplementing the basal chamber 
125 with one of four concentrations of genistein for 150 minutes. Genistein was prepared 
126 as a 10 mM stock in dimethyl sulfoxide (DMSO) owing to its limited solubility in 
127 ethanol [36]. Final concentrations of genistein supplemented were: 50 µM [10 µl 
128 stock in 3990 µl total KR (0.25 % v/v vehicle contribution), 100 µM (0.5 % v/v), 150 
129 µM (0.75 % v/v), or 180 µM (0.9 % v/v) (Figure 1).
130 Krebs Ringer medium was sampled (30 µl) apically and basally at regular intervals. 
131 TEER values remained in excess of 700 Ω∙cm-2 throughout all experiments 
132 conducted. Unless otherwise stated, transport experiments were done at 39ºC with the 
133 exception of sampling (~ 30 second duration) being performed at laboratory 
134 temperature (~ 21ºC). Medium sampled for analysis was not replaced in order to 
135 avoid unnecessary dilution. The apparent permeability coefficient (Papp) of genistein 
136 transport was also determined and is defined as: Papp = dQ.dt-1.(AC0)-1 where dQ/dt is 
137 the rate of genistein appearance (µM.min-1), C0 is the initial concentration of genistein 
138 (µM), and A is the surface area of the monolayer (cm2). Papp is therefore expressed in 
139 units of cm2.min-1 — adapted from [37].
140 2.6. Genistein Quantification
141 Samples collected from transport experiments were analyzed individually using an 
142 Agilent 1100 HPLC coupled with an Agilent Zorbax™ C-18 silica based column. 
143 Genistein eluted from the column with a buffer consisting of 99.5% methanol + 0.5% 
144 formic acid and detected at 288 nm. Quantification was performed relative to a 
145 standard curve (R2 = 0.9996).
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146 2.7. BOEC Supplementation for ivDOF Analyses
147 Upon reaching confluence BOECs were incubated in an air:liquid interface for 24 
148 hours at 39°C in 5% CO2 in culture medium basally supplemented with a final 
149 concentration of either: 100 µM genistein (in DMSO), 0.1% (v/v) DMSO, 14.7 pM E2 
150 (in ethanol), or 1% (v/v) ethanol. The ivDOF accumulated following 24 hours of 
151 BOEC exposure was subsequently stored at -20ºC until amino acid composition 
152 analysis was conducted by HPLC. 
153 2.8. Amino Acid Quantification
154 HPLC was used to measure 18 amino acids as previously described by Humpherson 
155 and coworkers [38]. In brief, amino acids present in ivDOF samples were derivatised 
156 with orthopthaldialdehyde (OPA) reagent supplemented with 1 mg/ml beta 
157 mercaptoethanol (β-ME) forming conjugates which emit fluorescence at 450 nm when 
158 excited at 330 nm. Following derivatisation, reverse phase chromatography was 
159 performed through an Agilent 1100 HPLC coupled with a Phenomenex HyperClone® 
160 5mm C-18 ODS 250 mm x 4.6 mm (extended) column. Gradient elution used two 
161 buffers: (A) 80% 83 mM sodium acetate (pH to 5.9 using glacial acetic acid), 19.5% 
162 methanol, 0.5% tetrahydrofuran (THF), and (B) 80% methanol and 20% 83 mM 
163 sodium acetate at 30°C for 60 minutes at a flow rate of 1.3 ml/min. Amino acids were 
164 separated based on retention time — as detected by fluorescence (absorbance unit 
165 peak) and quantified based on peak area relative to known standards [39].
166 2.9. Caco-2 Culture
167 As a ‘negative control’ the protocol for isolating fluid was repeated using cell-line 
168 derived absorptive colorectal epithelial adenocarcinoma cells (Caco-2). Specifically, 
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169 cells from the primarily absorptive HTB-37 human colon carcinoma (Caco-2) line 
170 were routinely cultured in T75 polystyrene flasks at 37°C in 5% CO2 in 95% air. 
171 Culture media comprised 12 ml high glucose DMEM supplemented with 15% foetal 
172 calf serum (v/v), 584 mg.l−1 glutamine, 1% minimum non-essential amino acids, 100 
173 U.ml−1 PenStrep and 0.25 μg.ml−1 amphotericin B. Media was renewed every 48 hours 
174 until cells reached 90–95% confluence, at which point the cells were extracted with 
175 trypsin–EDTA solution (3 ml) from each flask and seeded to TranswellTM membranes 
176 at a density of 0.26x106 cells.well−1. Media was replenished every 48 hours and for 20 
177 days until TEER was in excess of 900 Ω∙cm-2 — similarly to [40].
178 2.10. Statistical analysis
179 Statistical analyses were performed using Prism Graphpad 6 software for Apple 
180 Macintosh. Unless otherwise stated, all statistical analysis was two-way analysis of 
181 variance (ANOVA) followed by a Holm-Sidak non-parametric post hoc analysis.
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182 3.  Results
183 3.1.  Transport Kinetics
184 At all four concentrations, genistein permeated the in vitro bovine oviduct epithelial 
185 monolayer in a basal to apical direction in accordance with a broadly polynomial 
186 (non-linear) kinetic profile (Figure 2A). More specifically, genistein transport by 
187 BOECs was greater than the linear rate of spontaneous diffusion across a blank 
188 membrane (negative control) during the first 45 minutes of flux (Figure 2B). 
189 Following 60 minutes of transport, the rate of genistein movement across BOECs was 
190 the same as that across blank Transwell membranes (Figure 2C). Figure 2 therefore 
191 shows that genistein flux at all four concentrations measured occurred by two distinct 
192 phases of transport; an initial concentration-dependent burst phase (Figure 2B), 
193 followed by a slower concentration independent plateau phase (Figure 2C).
194 As a first approach to discover whether the burst and/or plateau phases of transport 
195 observed in Figure 2 were facilitated, the experiment was conducted at laboratory 
196 temperature (~21 ºC) in addition to the physiologically relevant incubator temperature 
197 of 39 ºC. Figure 3A shows that this temperature reduction significantly reduced 
198 genistein flux at 20 minutes. Taking this observation further and plotting the data 
199 from Figure 2 as the initial concentration of substrate vs. the initial rate of genistein 
200 transport (Figure 3B) shows that the data fit both classic facilitated and passive kinetic 
201 profiles with respective R2 values of 0.770 and 0868.
202 To determine whether there was a difference in the directionality of transport, 100 µM 
203 genistein was added to the apical (luminal) chamber and its depletion was measured 
204 in comparison to that from the basal to apical direction (Figure 4A). The total rate of 
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205 accumulation of genistein in the respective chambers was also measured (Figure 4B) 
206 and is presented as apparent permeability coefficients (Papp). These data indicated no 
207 difference in genistein flux directionality.
208 In addition, there was no difference in directionality when genistein was added at 
209 equilibrium (Figure 5A). However when this experiment was conducted it became 
210 apparent that the total (sum) of genistein present from both chambers decreased over 
211 time. Figure 5B (insert) is a condensed re-plot of the concentration of genistein 
212 internalised and/or degraded vs. time.
213 3.2.  Effects on ivDOF
214 Figure 6 shows that 100 µM genistein supplementation significantly modified the 
215 secretion by oviduct epithelia of 12 of the 18 amino acids measured. However the 
216 vehicle DMSO supplemented in isolation also influenced the amino acid composition 
217 of ivDOF relative to native – specifically serine, glutamine, glycine, threonine, 
218 arginine, and leucine secretion increased and histidine was decreased.
219 Figure 6 indicates that genistein does act independently of DMSO, but not as an E2 
220 analogue. Figure 6 moreover confirms that E2 independently alters ivDOF 
221 composition; with the same figure showing that 0.1% (v/v) ethanol only marginally 
222 impacts the secretion of histidine.
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223 4. Discussion
224 This study aimed to use a novel in vitro model of the bovine oviduct epithelium to 
225 investigate the effects of the dietary isoflavone genistein on luminal fluid 
226 composition.
227 4.1. Transport Kinetics
228 The first research question was (a) does genistein traverse the oviduct epithelium? 
229 Genistein crossed the oviduct epithelial membrane, and moreover appeared to do so in 
230 accordance with a biphasic (burst and plateau phase) kinetic profile (Figure 2). The 
231 initial burst phase of genistein flux occurred at a rate significantly higher than that of 
232 spontaneous diffusion across a Transwell membrane free of cells (Figure 2B), 
233 whereas the subsequent plateau phase was not (Figure 2C).
234 A secondary aim subsequently became to gain some insight into the potential 
235 mechanism of apical genistein flux. From an energetic perspective, the fact that 
236 genistein initially transverses the oviduct epithelium faster than the rate of diffusion 
237 (Figure 2B) indicates that genistein flux into the oviduct lumen in vitro could be 
238 driven by facilitated diffusion (passive transport) and/or primary active (ATP-
239 dependent) transport.
240 It is well established that active transport is temperature dependent [41]. Specifically, 
241 the rate of active transport decreases as the temperature deviates from physiological 
242 [42]. To test whether either phase (burst or plateau) of genistein flux might be active, 
243 the transport experiment was repeated at laboratory temperature (~21 ºC) (Figure 3A). 
244 Figure 3A shows that the ~18 ºC temperature reduction impaired genistein movement 
245 at 20 minutes, suggesting that the initial burst phase observed could be partly actively 
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246 mediated. 
247 In addition, passive transport is kinetically characterized as the positive linear 
248 relationship between the initial rate of transport and the initial concentration of 
249 substrate, whereas facilitated transport is kinetically characterized as a positive 
250 hyperbolic relationship between the initial rate of transport and the initial 
251 concentration of substrate. With this in mind, the experimentally determined initial 
252 rates of genistein transport relative to the initial concentration of genistein present 
253 were plotted (Figure 3B) and revealed that genistein permeation of the in vitro oviduct 
254 epithelium fitted both passive and facilitated curves with regression coefficients (R2) 
255 of 0.868 and 0.770 respectively.
256 In spite of this, when genistein was added to both apical and basal compartments of 
257 the Transwell membranes in equilibrium (Figure 5), there was no transport of 
258 genistein against a concentration gradient, and therefore no active movement. Hence 
259 the most likely mechanism underlying the initial burst phase of genistein flux is 
260 facilitated diffusion, with the decreased transport at 20 minutes at 21 ºC perhaps 
261 attributable to a decrease in Brownian motion [43] of genistein at 21 ºC and therefore 
262 impairing flux.
263 With regard to the plateau phase (Figure 2C), transport remaining unaffected by a 
264 reduction in temperature (Figure 3) and the rate of flux being comparable to the 
265 spontaneous diffusion of genistein, both imply the plateau phase of flux occurs by 
266 passive diffusion as genistein approaches equilibrium [44].
267 Spatially, three potential routes for genistein transport exist: (i) paracellular flux, (ii) 
268 intracellular movement or (iii) a combination of both routes. Paracellular flux is a 
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269 passive (ATP-independent) process whilst intracellular flux is generally an active 
270 (ATP-dependent) process [45]. Given the lack of evidence for actively mediated flux, 
271 we hypothesize that genistein transverses the in vitro oviduct paracellularly. An 
272 explanation for the facilitated burst phase observed could be the bovine oviduct 
273 epithelial phospholipid exterior serving as a surface catalyst, thereby accelerating of 
274 transport of this small hydrophobic molecule (Figure 1B) until close to equilibrium.
275 Although genistein has never been shown to cross the oviduct epithelium before, it 
276 has been established that genistein transverses other cellular monolayers in vitro 
277 including rat immortalised small intestinal epithelial (IEC-18) [46], human corneal 
278 epithelial cells (HCEC) [46], rat brain microvascular (BBB) endothelial cells [47], 
279 and human colorectal carcinoma epithelial (Caco-2) cells [47-50].
280 Yang and coworkers [47] reported a Papp of genistein flux across Caco-2 monolayers 
281 of 16.23 x 10-6 cm2.sec-1 which equates to 0.974 x 10-3 cm2.min-1 determined using 20 
282 µM genistein. Assuming linearity between Papp and genistein concentration [51] their 
283 Papp value would be 4.74 x 10-3 cm2.min-1 for 100 µM. The analogous value obtained 
284 in BBB cells was 4.03 x 10-6 cm2.min-1 [47]. The findings presented are similar to the 
285 value obtained across the oviduct epithelium: 4.43 x 10-3 cm2.min-1 (Figure 4B). From 
286 this it can determined that the oviduct epithelium is inherently less permeable to 
287 genistein than BBB cells but more so than Caco-2 cells, although these values are all 
288 broadly comparable.
289 The slight differences observed tentatively point to the observation that the 
290 permeability to genistein may be proportional to TEER; specifically cellular 
291 confluence is established at >500 Ω∙cm-2 in BBB cells [47], >700 Ω∙cm-2 in bovine 
292 oviduct epithelia [31], and >900 Ω∙cm-2 in Caco-2 cells [52]. This observation further 
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293 supports the notion that genistein flux across cellular monolayers in vitro is 
294 paracellular.
295 Regardless of the exact mechanism of transport, these data suggest that gametes and 
296 early embryos could be directly exposed to genistein in vivo. To evaluate whether 
297 genistein might pose indirect effects, the amino acid composition of ivDOF from 
298 BOECs treated with genistein was investigated.
299 4.2. Effects of Genistein Supplementation on ivDOF
300 Figure 6 suggests that 100 µM genistein supplementation significantly affected the 
301 secretion of 12 of 18 amino acids relative to native fluid. Specifically, serine, 
302 glutamine, glycine, threonine, arginine, tyrosine, valine, phenylalanine, isoleucine, 
303 leucine, and lysine were elevated in ivDOF from genistein treated BOECs relative to 
304 native (untreated), whereas histidine was reduced.
305 However conducting the vehicle control experiment showed that DMSO also has an 
306 effect on the amino acid composition of ivDOF (Figure 6). The effect of genistein 
307 appeared to be independent of DMSO with regard to the secretion of 5 amino acids 
308 measured — specifically glutamine, glycine, arginine, leucine, lysine and isoleucine 
309 (Figure 5C). It is difficult to explain this pattern since these 5 amino acids do not 
310 share common transporters or chemical characteristics. Nonetheless, although it is 
311 challenging to evaluate any specific effect that genistein is having on the in vitro 
312 oviduct beyond that of DMSO, it appears that genistein does alter the amino acid 
313 composition of ivDOF. The impact of the modifications of concentrations of each of 
314 these amino acids on embryo development is yet to be confirmed, however it is likely 
315 that there will be an embryo-response to such changes, given the importance of these 
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316 amino acids in early development. For example, glutamine serves as a critical energy 
317 source [53], whereas glycine plays an important osmoregulatory function [54]. In 
318 light of this, the aim became to evaluate whether genistein acts on the in vitro oviduct 
319 epithelium as an E2 analogue.
320 The affinity of genistein for ERα and and ERβ is 0.7% and 13% respectively of that 
321 for the endogenous ligand E2 [26]. Although not a high percentage, the corresponding 
322 dissociation constants can be calculated to be as low as 7 nM for ERα and 0.6 nM for 
323 ERβ. Given these high affinities of genistein for the oestrogen receptors, it is 
324 unsurprising that genistein exerts oestrogenic effects by activating oestrogen response 
325 element (ERE) regulated genes in several mouse tissues, as determined by ERE-
326 luciferase linked reporter assays [55], activating ERE regulated genes in human breast 
327 cancer cells as determined by qRT-PCR mRNA quantification [56], and by means of 
328 modulating rat behaviour [57].
329 To evaluate whether genistein may be acting on the in vitro oviduct as an E2 mimic, 
330 BOECs were treated with E2 at a physiological concentration. Although one might 
331 assume that the amino acid profiles of ivDOF obtained from genistein and E2 would 
332 be similar, it was observed that 7 of the 18 amino acids measured were significantly 
333 different. The data therefore suggest that genistein does impact the composition of 
334 oviduct secretions in vitro but not as an E2 mimic. However given the effects of 
335 DMSO, future work is required to confirm this. 
336 4.3. Additional Observations
337 From a model validation perspective, the fact that apical accumulation of fluid was 
338 not detected in Caco-2 cells, an absorptive epithelium grown on Transwell 
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339 membranes, provides confidence in the experimental protocol employed in addition to 
340 the secretory nature of the oviduct cells used in the in vitro oviduct model.
341 4.4. Summary
342 Numerous studies have been conducted on the bioavailability of isoflavones in adults 
343 [58-62] but little is known about the possible delivery and effects of flavonoid 
344 conjugates on specific tissues, including the oviduct. The data presented show that (a) 
345 the oviduct epithelium is permeable to genistein, and facilitates its transport into the 
346 lumen in accordance with a biphasic kinetic profile, and (b) that genistein presence 
347 impacts the amino acid composition of ivDOF.
348 Within the wider context of biology the results demonstrate the potential use of this in 
349 vitro model in characterising the transport or barrier properties of the oviduct towards 
350 a range of circulating xenobiotics.
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565 Figure Legends
566 Figure 1. The molecular structures of A: Genistein-7-Glucoside (Genistin), B: 
567 Genistein, C: E2, D: Dimethyl Sulfoxide (DMSO), and E: Ethanol. F: Schematic 
568 diagram of the basic experimental premise of investigating the transport kinetics of 
569 genistein across the bovine oviduct epithelium at liquid-liquid interface (Krebs Ringer 
570 medium) at four concentrations, and G: An analogous schematic highlighting the air-
571 liquid interface (culture medium) based experimental premise of investigating the 
572 impact of genistein on ivDOF composition in the capacity of a E2 mimic in 
573 conjunction with associated vehicular controls: DMSO and ethanol.
574 Figure 2. A: The apical accumulation of genistein across the in vitro bovine oviduct 
575 epithelial monolayer at four concentrations (50 µM, 100 µM, 150 µM and 180 µM) 
576 over 150 minutes. B: Initial burst phase genistein flux across BOECs in addition to 
577 across empty Transwell membranes [negative control (N)]. C: Secondary plateau 
578 phase genistein transport across BOECs and blank membranes (all n=3 ± SD). 
579 Statistically significant differences were determined by 2-way ANOVA coupled with 
580 the Holm-Sidak post hoc test. * represents p ≤ 0.05 and **** p ≤ 0.0001.
581 Figure 3. A: The apical flux of genistein (100 µM) across the BOEC epithelium at 
582 physiological (39 ºC) and lab (21 ºC) temperature (n=3 ± SD). One statistically 
583 significant difference was determined by unpaired t-test (p=0.002). B: Genistein 
584 transport data plotted as the initial rate of transport (µM.min-1) vs. the initial genistein 
585 concentration (µM), showing a good fit to both passive (R2 = 0.868) and facilitated 
586 (R2 = 0.770) kinetic profiles (n=3).
587 Figure 4. A: The respective accumulation of genistein in each compartment plotted as 
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588 concentration (µM) vs. time (minutes) (n=4 ± SD). B: The corresponding Papp values 
589 of the bovine oviduct epithelium to genistein accumulation was 4.43 x 10-3 cm2.min-1 
590 (basal to apical; n=7 ± SEM) and 4.26 x 10-3 cm2.min-1 (apical to basal; n=7 ± SEM) 
591 with a genistein concentration of 100 µM.
592 Figure 5. A: The concentration of apical and basal genistein vs. time (minutes) when 
593 added in equilibrium at 50 µM.chamber-1. B: The depletion of total genistein (all n=3 
594 ± SD).
595 Figure 6. The amino acid composition of ivDOF accumulated apically from native 
596 (untreated) BOECs (n=3 ± SD) (black) vs that from BOECs basally treated with 100 
597 µM genistein (n=6 ± SD) (grey) vs ivDOF derived from oviduct epithelia exposed to 
598 14.7 pM 17β-oestradiol (n=3 ± SD) (red) vs ivDOF derived from BOECs 
599 supplemented with 1% v/v dimethyl sulfoxide (DMSO) - the genistein vehicle control 
600 (n=3 ± SD) (green) vs ivDOF derived from BOECs supplemented with 0.1% v/v 
601 ethanol – the 17β-oestradiol vehicle control (n=3 ± SD). ivDOF accumulated over 24 
602 hours. Statistically significant differences were determined by two-way ANOVA 
603 followed by a Holm-Sidak post hoc analysis, where a represents p ≤ 0.0001, b 
604 represents p ≤ 0.001, c represents p ≤ 0.01, and d represents p ≤ 0.05.

























©2018, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Abstract
The dietary derived isoflavone and oestrogen analogue, genistein, is known to perturb 
fundamental reproductive events such as implantation and embryo cleavage. However 
the question of whether genistein is able to traverse the oviduct epithelial monolayer 
and impact oviduct fluid secretion remains unclear. This study tests these research 
questions using a bioartificial oviduct to show that genistein permeates the oviduct 
lumen in vitro with a biphasic (burst and plateau) kinetic profile, faster than 
spontaneous diffusion, and alters the amino acid composition of in vitro derived 
oviduct fluid (ivDOF) but not as an oestrogen analogue. In addition to offering 
insights into the potential mechanisms of these findings, this manuscript demonstrates 
the potential to use the bioartificial oviduct model to characterise the transport or 
barrier properties of the oviduct towards a range of circulating xenobiotics.
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Highlights
This manuscript utilises an existing technology (bioartificial oviduct) for the novel 
application of investigating the effects of genistein – a dietary derived isoflavone 
known to impair reproductive capacity – on the oviduct in vitro. The data show that 
genistein transverses the oviduct epithelium biphasically and moreover impacts the 
luminal secretion of amino acids. This could explain, in part, previous reports of 
genistein perturbing central reproductive events such as implantation and cleavage.
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